Compare Fidelity National Information Servcs Inc (FIS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Novartis AG — how do they compare? Fidelity National Information Servcs Inc trades at $42.67 (market cap $21.92B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 13.6× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.14%). Which is the better fit depends on your goals.
| FIS | NVS | |
|---|---|---|
Market Cap | $21.92B | $298.18B |
Sector | Technology | Health |
52-Week High | $72.77 | $168.62 |
52-Week Low | $37.72 | $119.31 |
Enterprise Value | $42.43B | $339.50B |
Dividend Yield | 4.14% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.77, down slightly on the day, with a bearish technical signal. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, driven by Banking Solutions growth. Recent news highlights the global expansion of its Digital One Commercial platform into the APAC region. Valuation metrics appear attractive with a P/E of 6.57 and a consensus price target of $50.20, though the company lowered its full-year Capital Markets outlook.
The outlook is mixed; strong fundamentals and analyst support suggest upside potential, but near-term price action is weak and execution risks in the Capital Markets segment pose a challenge. The stock offers value but requires monitoring of the revised guidance and competitive pressures in the fintech space.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
